SAB Biotherapeutics, Inc. (SABS) has a consensus analyst rating of Buy, based on 6 analysts covering the stock. Of those, 5 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for SABS is $7.00, representing a +81.3% upside from the current price of $3.86. Price targets range from a low of $7.00 to a high of $7.00.
